Acadia Pharmaceuticals | ACAD - Operating Profit


Acadia Pharmaceuticals reported $17.39M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Prothena USD -27.21M 12.55M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025